Syncom Formulations (India)
Syncom Formulations (India) Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Syncom Formulations (India) Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Syncom Formulations (India) Ltd trades at a P/E of 17.62× and P/B of 3.48×.
Valuation
Profitability
Growth
Financial Health
Syncom Formulations (India) Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Syncom Formulations (India) Ltd, switchable between annual and quarterly views, consolidated or standalone.
Syncom Formulations (India) Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,344.2 Cr and reported EPS of ₹0.81.
| Period | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue from Operations | 224 | 263 | 465 | 489 |
| Other Income | 15 | 14 | 17 | 31 |
| Total Income | 239 | 277 | 482 | 521 |
| Cost of Goods Sold (COGS) | 142 | 157 | 307 | 284 |
| Gross Profit | 83 | 107 | 158 | 205 |
| +Operating Expenses | 63 | 77 | 104 | 127 |
| EBITDA | 20 | 30 | 54 | 77 |
| +Non-Operating Expenses | 8 | 9 | 6 | 8 |
| Profit Before Tax (PBT) | 27 | 34 | 66 | 101 |
| +Tax Expense | 7 | 9 | 16 | 25 |
| Profit After Tax (PAT) | 20 | 25 | 49 | 76 |
| Earnings Per Share (EPS) | 0.21 | 0.27 | 0.53 | 0.81 |
| Diluted Shares Outstanding (Nos.) | 94 | 94 | 94 | 94 |
| +Additional Disclosures | 356 | 407 | 729 | 700 |
| Sales Growth % | — | 17.45 | 76.55 | 5.20 |
| YoY Sales Growth % | — | 17.45 | 76.55 | 5.20 |
| Material Cost % | 44 | 50 | 60 | 45 |
| Employee Cost % | 12 | 13 | 11 | 14 |
| Other Cost % | 17 | 16 | 11 | 12 |
| OPM % | 9 | 11 | 12 | 16 |
| Tax % | 24 | 25 | 25 | 24 |
| Profit Growth % | — | 26.13 | 95.28 | 54.62 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 15 | 25 | 49 | 71 |
Syncom Formulations (India) segment analysis: revenue and profit mix.
Disclosed business segments at Syncom Formulations (India) with their share of revenue and profit, switchable between consolidated and standalone reporting.
Syncom Formulations (India) discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Syncom Formulations (India) Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Syncom Formulations (India) Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Syncom Formulations (India) Ltd's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust quarterly profit growth of 106.00% indicates strong operational efficiency.
Healthy ROCE of 18.70% and ROE of 15.60% show efficient capital use.
Very low debt-to-equity ratio of 0.01 ensures strong financial stability.
Strong 5-year Free Cash Flow CAGR of 46.22% demonstrates excellent cash generation.
Consistent revenue growth with 33.98% quarterly YoY increase.
What can break it.
Zero dividend yield (0.00%) may deter income-focused investors.
Low institutional holdings (FII 0.10%, DII 0.00%) indicate limited confidence.
Stock trading significantly below 52-week high suggests recent downward momentum.
Negative price returns over 13-week (-7.67%) and YTD (-18.24%) periods.
High beta (1.49) indicates higher stock volatility compared to the market.
What would change my mind.
Trim if P/E re-rates above 23. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 15%. The operating engine is no longer compounding capital efficiently.
Syncom Formulations (India) Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Syncom Formulations (India) Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Syncom Formulations (India) Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Syncom Formulations (India) Ltd — derived from the live tape, not yesterday's close.
Syncom Formulations (India) Ltd last traded at ₹14.27 with an intraday range of ₹14–₹14.35 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹14.27| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 15.11 | +0.84 | +5.91% |
| R3 | 14.76 | +0.49 | +3.46% |
| R2 | 14.56 | +0.29 | +2.01% |
| R1 | 14.41 | +0.14 | +1.00% |
| PIVOT | 14.21 | -0.06 | -0.44% |
| CURRENT | 14.27 | — | — |
| S1 | 13.36 | -0.91 | -6.35% |
| S2 | 13.71 | -0.56 | -3.90% |
| S3 | 13.86 | -0.41 | -2.90% |
| S4 | 14.06 | -0.21 | -1.45% |
SYNCOMF is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: 14 ~ 14.28
Trading Above opening range, showing Bullishness
Syncom Formulations (India) Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Syncom Formulations (India) Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Syncom Formulations (India) Ltd stood at 56.6% of traded volume, against a 20-day average of 47.6%.
Syncom Formulations (India) announcements: results, concalls, ratings, M&A.
Filings Syncom Formulations (India) sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Syncom Formulations (India) files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 42 documents below.
Copy of Newspaper Publication
Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
General Updates
Syncom Formulations (India) Limited has informed the Exchange about General Updates
Trading Window
Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Copy of Newspaper Publication
Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
Syncom Formulations (India) dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Syncom Formulations (India) has declared, sequenced by announce and record date.
Syncom Formulations (India) corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Syncom Formulations (India) Ltd: business, sector, key facts.
What Syncom Formulations (India) Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Syncom Formulations (India) Ltd operates in the Healthcare, listed as NSE: SYNCOMF, BSE: 524470.
Syncom Formulations (India) Limited is a pharmaceutical company primarily focused on the manufacturing, marketing, and sale of pharmaceutical formulations within India. Their operations are structured across three key segments: manufacturing and dealing in pharmaceutical drugs and formulations, trading of commodities, and renting of properties. The core of their business lies in the production and distribution of a wide array of pharmaceutical products.
Their pharmaceutical product portfolio is extensive and covers various therapeutic areas. This includes antibiotics and anti-infectives to combat bacterial infections, anthelmintics for parasitic worm infestations, antimalarial drugs for malaria treatment, and medications targeting cardiac (heart-related) conditions. Beyond these, they offer formulations for dermatological (skin), gastrointestinal, gynecological, ophthalmological (eye), orthopedic, and pediatric applications. This broad range of offerings demonstrates a commitment to providing solutions across a diverse spectrum of healthcare needs.
In addition to their core pharmaceutical offerings, Syncom Formulations also markets and distributes a line of health and wellness products under the Cratus brand. These products, categorized as life care, evolve, and right nutrition products, likely represent an effort to expand their reach beyond prescription medications and cater to a broader consumer base interested in preventative healthcare and supplementary nutrition. This diversification strategy allows them to engage a wider segment of the market.
The company’s operational scope extends beyond pharmaceutical manufacturing and sales. They actively engage in the trading of commodities, suggesting involvement in the procurement of raw materials and potentially other related goods. Further, the renting of properties indicates a supplementary income stream, possibly through the ownership of facilities used in their operations or through independent real estate holdings. This diversification mitigates risk and provides additional revenue streams.
Syncom Formulations distributes its products in various dosage forms, showcasing a commitment to offering flexible and convenient treatment options for patients. These forms include tablets, capsules, ointments, injections, oral liquids, and effervescent formulations, reflecting adaptability to the needs of different medical conditions and patient preferences. The company also exports its products, demonstrating a presence in international markets beyond India’s borders.
Questions investors ask about Syncom Formulations (India) Ltd (SYNCOMF).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Syncom Formulations (India) Ltd (SYNCOMF)?
The current share price of Syncom Formulations (India) Ltd (SYNCOMF) is ₹14.27. Today, the stock has gained by ₹0.36 (2.59%), trading in a range of ₹14 to ₹14.35. The stock opened at ₹14 with a trading volume of 14,66,441 shares.
02Is Syncom Formulations (India) Ltd stock a good investment for long-term?
Syncom Formulations (India) Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,344.2 crores, P/E ratio of 17.62, ROE of 20.19%, and ROCE of 18.70%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Syncom Formulations (India) Ltd stock?
The 52-week high price of Syncom Formulations (India) Ltd (SYNCOMF) is ₹0, while the 52-week low is ₹0. Currently trading at ₹14.27, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Syncom Formulations (India) Ltd stock at the current price?
Whether to buy Syncom Formulations (India) Ltd stock at ₹14.27 depends on multiple factors. The stock is currently trading with a P/E ratio of 17.62 and P/B ratio of 3.48. Today's performance shows a gain of 2.59%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Syncom Formulations (India) Ltd and when is the next dividend?
Syncom Formulations (India) Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹14.27, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd's key financial metrics include: P/E Ratio: 17.62, P/B Ratio: 3.48, ROE: 20.19%, ROCE: 18.70%, Dividend Yield: 0.00%, EPS: ₹0.81, Book Value: ₹4.1, and Debt-to-Equity: 0.36. The company's market cap stands at ₹1,344.2 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Syncom Formulations (India) Ltd stock performing today in the market?
Syncom Formulations (India) Ltd stock opened at ₹14 and is currently trading at ₹14.27, showing a gain of ₹0.36 (2.59%). The intraday high is ₹14.35 and low is ₹14. The trading volume stands at 14,66,441 shares, indicating strong market participation today.
08What is the P/E ratio of Syncom Formulations (India) Ltd and what does it indicate?
Syncom Formulations (India) Ltd has a Price-to-Earnings (P/E) ratio of 17.62, which means investors are willing to pay ₹17.62 for every ₹1 of earnings. With an EPS of ₹0.81, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Syncom Formulations (India) Ltd (SYNCOMF) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy